



BioLineRx to present at the BIO CEO & Investor Conference

February 7, 2012

Jerusalem, Israel, February 7, 2012 - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2012 BIO CEO & Investor Conference in New York.

Dr. Savitsky and Mr. Serlin are scheduled to present at 10:00 AM EST on Tuesday, February 14th. A live Webcast of the presentation will be available on the BioLineRx Website at <http://www.biolinerx.com/default.asp?pageid=63&itemid=107>. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

About BioLineRx

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, is currently undergoing a pivotal CE-Mark registration trial and has been out-licensed to Ikaria Inc. for a total deal value of \$282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has 13 products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit www.biolinerx.com.

Contact:

KCSA Strategic Communications

Garth Russell, 1 212-896-1250

grussell@kcsa.com

or

Todd Fromer, 1 212-896-1250

tfromer@kcsa.com

or

BioLineRx Ltd.

Tsipi Haitovsky, +972-3-6240871

Public Relations

tsipih@netvision.net.il